14-3-3ε plays a role in cardiac ventricular compaction by regulating the cardiomyocyte cell cycle

Molecular and Cellular Biology

Volumn 32, Issue 24, 2012, Pages 5089-5102

  Kosaka, Yasuhiro ^a   Cieslik, Katarzyna A ^b,d   Li, Ling ^a   Lezin, George ^a   Maguire, Colin T ^a   Saijoh, Yukio ^a   Toyo oka, Kazuhito ^c   Gambello, Michael J ^b,f   Vatta, Matteo ^d   Wynshaw Boris, Anthony ^c   Baldini, Antonio ^e   Yost, H Joseph ^a   Brunelli, Luca ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; PROTEIN 14 3 3; PROTEIN 14 3 3 EPSILON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; DOWN REGULATION; EMBRYO; FEMALE; GENE DELETION; HEART DEVELOPMENT; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THICKNESS; UPREGULATION;

14-3-3 PROTEINS; ANIMALS; BASE SEQUENCE; CELL CYCLE; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; FETAL HEART; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MYOCYTES, CARDIAC; ONCOGENE PROTEINS;

EID: 84871908867     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00829-12     Document Type: Article

References (67)

1. Aitken A, et al. 1992. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem. Sci. 17:498-501.
2. Arunamata A, Punn R, Cuneo B, Bharati S, Silverman NH. 2012. Echocardiographic diagnosis and prognosis of fetal left ventricular noncompaction. J. Am. Soc. Echocardiogr. 25:112-120.
3. Breckenridge RA, Anderson RH, Elliott PM. 2007. Isolated left ventricular non-compaction: the case for abnormal myocardial development. Cardiol. Young 17:124-129.
4. Brugarolas J, et al. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
5. Brunelli L, Cieslik KA, Alcorn JL, Vatta M, Baldini A. 2007. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3e in human endothelial cells via CCAAT/enhancer binding protein-beta. Circ. Res. 100: e59-e71. doi:10.1161/01.RES.0000260805.99076.22.
6. Chen H, et al. 2004. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131:2219-2231.
7. 1 checkpoint control. Cell 82:675- 684.
8. 1 cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12:676-684.
9. Elliott P, et al. 2008. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 29:270-276.
10. Engel FB, et al. 1999. A mammalian myocardial cell-free system to study cell cycle reentry in terminally differentiated cardiomyocytes. Circ. Res. 85:294-301.
11. Freedom RM, et al. 2005. The morphological spectrum of ventricular noncompaction. Cardiol. Young 15:345-364.
12. Fu H, Subramanian RR, Masters SC. 2000. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40:617- 647.
13. kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277:28706-28713.
14. kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 278:49254-49260.
15. Geng Y, et al. 2003. Cyclin E ablation in the mouse. Cell 114:431- 443.
16. Heallen T, et al. 2011. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332:458-461.
17. Hermeking H, Benzinger A. 2006. 14-3-3 proteins in cell cycle regulation. Semin. Cancer Biol. 16:183-192.
18. Hoy TG. 1990. Flow cytometry: clinical applications in haematology. Baillieres Clin. Haematol. 3:977-998.
19. Ichida F. 2009. Left ventricular noncompaction. Circ. J. 73:19-26.
20. Jagemann LR, et al. 2008. The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. J. Biol. Chem. 283:17450-17462.
21. Jung J, Kim TG, Lyons GE, Kim HR, Lee Y. 2005. Jumonji regulates cardiomyocyte proliferation via interaction with retinoblastoma protein. J. Biol. Chem. 280:30916-30923.
22. Kastner P, et al. 1994. Genetic analysis of RXRα developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 78:987-1003.
23. Kochilas LK, Li J, Jin F, Buck CA, Epstein JA. 1999. p57Kip2 expression is enhanced during mid-cardiac murine development and is restricted to trabecular myocardium. Pediatr. Res. 45:635- 642.
24. Lau JM, et al. 2007. The 14-3-3τ phosphoserine-binding protein is required for cardiomyocyte survival. Mol. Cell. Biol. 27:1455-1466.
25. Lau JM, Wu C, Muslin AJ. 2006. Differential role of 14-3-3 family members in Xenopus development. Dev. Dyn. 235:1761-1776.
26. Lavine KJ, et al. 2005. Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev. Cell 8:85-95.
27. 1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am. J. Physiol. 275:H814-H822.
28. Li P, et al. 2011. IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. Development 138:1795- 1805.
29. Limongelli G, et al. 2010. Right ventricular hypertrabeculation associated with double-outlet left ventricle: exaggeration of a normal pattern or right ventricular cardiomyopathy? J. Cardiovasc. Med. (Hagerstown) 11:193- 195.
30. Luk SC, et al. 1998. Developmental regulation of 14-3-3e isoform in rat heart. J. Cell. Biochem. 68:195-199.
31. Maron BJ, et al. 2006. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807- 1816.
32. McConnell JE, Armstrong JF, Hodges PE, Bard JB. 1995. The mouse 14-3-3e isoform, a kinase regulator whose expression pattern is modulated in mesenchyme and neuronal differentiation. Dev. Biol. 169:218- 228.
33. Menon SC, et al. 2007. Fetal and neonatal presentation of noncompacted ventricular myocardium: expanding the clinical spectrum. J. Am. Soc. Echocardiogr. 20:1344-1350.
34. Mikawa T, Fischman DA. 1996. The polyclonal origin of myocyte lineages. Annu. Rev. Physiol. 58:509-521.
35. Milton AH, Khaire N, Ingram L, O'Donnell AJ, La Thangue NB. 2006. 14-3-3 proteins integrate E2F activity with the DNA damage response. EMBO J. 25:1046-1057.
36. Momoi N, et al. 2012. Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction. Eur. J. Pediatr. 171:515-520.
37. Mongiovi M, Fesslova V, Fazio G, Barbaro G, Pipitone S. 2010. Diagnosis and prognosis of fetal cardiomyopathies: a review. Curr. Pharm. Des. 16:2929-2934.
38. Muslin AJ, Tanner JW, Allen PM, Shaw AS. 1996. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84:889-897.
39. Kip2 during mouse development. Anat. Embryol. (Berl.) 203:77- 87.
40. kip1. Biochem. Biophys. Res. Commun. 282:853- 860.
41. 1 arrest and Sphase checkpoint function. Nat. Biotechnol. 22:993-1000.
42. Ormerod MG, Payne AW, Watson JV. 1987. Improved program for the analysis of DNA histograms. Cytometry 8:637- 641.
43. Pagano M, et al. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682- 685.
44. Pashmforoush M, et al. 2004. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 117:373-386.
45. Pasumarthi KB, Field LJ. 2002. Cardiomyocyte cell cycle regulation. Circ. Res. 90:1044-1054.
46. kip1 knockout mice. Circ. Res. 85:117-127.
47. Pozuelo Rubio M, et al. 2004. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem. J. 379:395- 408.
48. kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:492-503.
49. Saurin AT, et al. 2008. The regulated assembly of a PKCe complex controls the completion of cytokinesis. Nat. Cell Biol. 10:891-901.
50. Shou W, et al. 1998. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391:489-492.
51. 1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev. Cell 14: 298-311.
52. Steinacker P, et al. 2005. Unchanged survival rates of 14-3-3γ knockout mice after inoculation with pathological prion protein. Mol. Cell. Biol. 25:1339-1346.
53. Sucov HM, et al. 1994. RXRα mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 8:1007-1018.
54. Towbin JA. 2010. Left ventricular noncompaction: a new form of heart failure. Heart Fail. Clin. 6:453- 469.
55. Towbin JA, Bowles NE. 2002. The failing heart. Nature 415:227-233.
56. Toyo-oka, K, et al. 2003. 14-3-3e is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nat. Genet. 34:274-285.
57. Wang B, et al. 2004. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131:4477- 4487.
58. Wang W, Ungermannova D, Jin J, Harper JW, Liu X. 2004. Negative regulation of SCFSkp2 ubiquitin ligase by TGF-β signaling. Oncogene 23:1064-1075.
59. 1 peak. Cytometry 8:1- 8.
60. Weiford BC, Subbarao VD, Mulhern KM. 2004. Noncompaction of the ventricular myocardium. Circulation 109:2965-2971.
61. Whitham JK, Hasan BS, Schamberger MS, Johnson TR. 2008. Use of cardiac magnetic resonance imaging to determine myocardial viability in an infant with in utero septal myocardial infarction and ventricular noncompaction. Pediatr. Cardiol. 29:950-953.
62. Wilker EW, Grant RA, Artim SC, Yaffe MB. 2005. A structural basis for 14-3-3σ functional specificity. J. Biol. Chem. 280:18891-18898.
63. Winter S, et al. 2008. 14-3-3 proteins recognize a histone code at histone H3 and are required for transcriptional activation. EMBO J. 27:88-99.
64. Xin M, et al. 2011. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci. Signal. 4:ra70. doi:10.1126/scisignal.2002278.
65. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ. 2000. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 19:349-358.
66. Yaffe MB, et al. 1997. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91:961-971.
67. Zambrano E, Marshalko SJ, Jaffe CC, Hui P. 2002. Isolated noncompaction of the ventricular myocardium: clinical and molecular aspects of a rare cardiomyopathy. Lab. Invest. 82:117-122.